Iliofemoral DVT: Miminizing Post-Thrombotic Syndrome
|
|
- Florence Jacobs
- 5 years ago
- Views:
Transcription
1 Iliofemoral DVT: Miminizing Post-Thrombotic Syndrome Catherine K. Chang, MD FACS Vascular Surgery San Diego Southern California Permanente Medical Group Acute Deep Venous Thrombosis Incidence & Outcomes 117 of 100,000 person years in US Recurrent DVT in ~30% within 5-10 years Post-thrombotic syndrome (PTS) in ~40% within 2 years Rutherford s Vascular Surgery 8 th Edition Post-thrombotic syndrome (PTS) PTS: Villalta scale 20-50% of DVT patients in 1-2 years Symptoms and signs vary Severe in 5-10% Kahn SR. Thrombosis Research 2011; 127:S89-92 Vasquez SR et al. Best Practice & Research Clinical Haematology 2012; 25: PTS after Acute DVT Prospective study of 387 patients Villalta scale from 1 to 24 months PTS Severity Prevalence Mild: % Moderate: % Severe: >14 or ulcer 3% Predictors of Higher Scores Increase in Score Common femoral or iliac DVT (+1.29 to +3.16) Previous ipsilateral DVT (+0.69 to +2.87) Severity at 1 month +1.97, +5.03, DVT Classification Proximal vs distal LET classification I - isolated calf vein thrombosis II - femoral-popliteal vein thrombosis III - common femoral and/or iliac vein thrombosis IV - IVC thrombosis Non-occlusive thrombus in common femoral vein graded as class II Kahn SR et al. Ann Intern Med 2008; 149: Strijkers R. et al Phlebology 2015; 30(1S):
2 Duplex Iliofemoral DVT Iliofemoral DVT: Natural History Common channel of venous drainage from involved lower extremity obliterated Sequela with anticoagulation alone Persistent obstruction 70% Chronic venous insufficiency >90% Venous claudication 40% Venous ulceration 15% Recurrent VTE 11.8% in 3 months OR 2.4 (95% CI 0.95 to 5.9) Treatment of Acute DVT Anticoagulation Compression stockings Catheter directed thrombolysis (CDT) Pharmacomechanical adjuncts Venoplasty and stenting Akesson H et al. Euro J Vasc Surg 1990; 4(1): 43-8 Delis KT et al. Ann Surg 2004; 239(1): Douketis JD et al. Am J Med 2001; 110(7):515-9 CDT: Meta-analysis 4 studies: thrombolysis vs anticoagulation Quality generally low Egypt Trial 1 st randomized controlled trial N=35 CDT + anticoagulation (N=18) Anticoagulation alone (N=17) Iliofemoral DVT <10 days old Streptokinase: pulse spray continuous infusion venogram 12 hour intervals Venous function at 6 months Extent of residual thrombus Venous reflux and venous outflow Casey E et al. J Vasc Surg 2012; 55: Elsharawy M. Eur J Vasc Endovasc Surg 2002; 24:
3 Egypt Trial Egypt Trial Catheter directed thrombolysis was better than anticoagulation alone No major bleeding complications Symptomatic PE 6% - anticoagulant group Elsharawy M. Eur J Vasc Endovasc Surg 2002; 24: Elsharawy M. Eur J Vasc Endovasc Surg 2002; 24: Norwegian randomized trial N=209 CDT + anticoagulation (N=101) Anticoagulation alone (N=108) 1 st DVT above mid thigh 21 days Alteplase infusion venogram daily Adjunctive angioplasty and stenting (<50% stenosis) Co-primary outcomes Iliofemoral patency at 6 months PTS by Villalta score at 24 months PTS 24 months: ARR 14.4% (95% CI: ) with CDT, NNT 7 Iliofemoral patency: ARR 24.4% (95% CI: ; P=.001) Iliofemoral DVT <50% Compliance with compression stockings higher in CDT group % of patients on anticoagulation with INR Months 24 months CDT Control 3
4 Extent of Thrombolysis Achieved 11% 48% 41% Complete 50-99% <50% Adjunctive Procedures 1% 17% 57% 25% Complications CDT: Mean duration 2.4 days (SD 1.1) 20 bleeding 3 major, 5 clinically relevant CDT should be considered in 4 non-bleeding patients No ICH, no PE, with no deathshigh proximal DVT and low risk of bleeding Anticoagulation alone: no bleeding AngioJet Venous stents Balloon angioplasty None : Results at 5 years N=176 patients (84% of intial 209) CDT N=87 ARR 28% (95% CI: 14-42), NNT = 4 No difference in QOL Anticoagulation N=89 P value PTS 43% 71% <.0001 Severe PTS 5% 1% Multicenter, randomized, open-label, assessor blinded, controlled trial Symptomatic, proximal DVT <14 days Iliac, common femoral, &/or femoral vein DVT No prior DVT within 2 years Randomization stratified Anatomical extent (common femoral ± iliac vein) Primary outcome PTS at 24 months Villalta Scale Haig et al. Lancet Haematol 2016; 3(2):e64-71 Vedantham S et al. Am Heart J 2013; 165: Anticoagulation Heparin + Coumadin Duration 3 months PCDT Pharmacomechanical catheter directed thrombolysis mmhg knee high compression stockings at 10 day FU PCDT Good inflow into popliteal vein Isolated thrombolysis Trellis Powerpulse thrombolysis AngioJet Poor inflow into popliteal vein Infusion-first thrombolysis rt-pa infusion at 0.01 mg/kg/hr Max rt-pa 35 mg, 30 hours Adjunctive treatment PTA ± stenting of obstructive lesions Vedantham S et al. Am Heart J 2013; 165: Vedantham S et al. Am Heart J 2013; 165:
5 N = 692 patients, 24 month FU PCDT N = 337 Anticoagulation N = 355 No difference in any PTS (Villalta >5 or ulcer) No difference in QoL measures No difference when stratified by level of DVT P value PTS 46.7% 48.2%.56 Generic QoL (SF-36) Venous QoL (VEINES) PCDT N = 337 Anticoagulation N = 355 PCDT reduced PTS severity Difference in PTS severity seen mostly in iliofemoral DVT patients P value Moderate or Severe PTS 17.9% 23.7%.035 Iliofemoral DVT 18.4% 28.2% Femoropopliteal DVT 17.1% 18.1% Vedantham S et al NEJM 2017; 377: PCDT N = 337 Anticoagulation N = 355 PCDT less effective in patients 65 years Limitations: Losses to FU (2/3 risk in control of group) PTS.? Generalizability: 28,507 pts met inclusion criteria Sample size limited power in subgroup analysis Multiple PCDT methods P value Recurrent DVT 12.5% 8.5%.09 Bleeding Among patients 4.5% with 1.7% acute.034 Major bleeding 1.7% 0.3%.049 proximal DVT, addition of PCDT did not result in lower Mean thrombus removal 76% Vedantham S et al NEJM 2017; 377: Residual Thrombus after CDT Retrospective study: N=71 Iliofemoral DVT CDT Quantity of residual thrombus on venogram Blinded assessment Group 1: 50% Group 2: >50% Villalta and CEAP scores: N=63 Blinded assessment Residual Thrombus after CDT Group 1 50% Group 2 >50% P value Mean clot lysis 42% 85% CEAP (median) Villalta (mean) Residual thrombus associated with increased risk of PTS Comerota A et al. J Vasc Surg 2012; 55: Comerota A et al. J Vasc Surg 2012; 55:
6 Comparative Safety of CDT Observational study: NIS from Proximal or caval DVT CDT + Anticoagulation in 4.1% Increase from 2.3% 2005 to 5.9% in 2010 Propensity scores 2 matched groups of N=3594 patients Outcomes Primary: in-hospital mortality Secondary: bleeding complications Comparative Safety of CDT Small trials may underestimate harm of CDT No significant difference in mortality Increased blood transfusion, ICH, PE and IVC filter placement with CDT. Bashir R et al. JAMA Intern Med 2014; 174(9): Bashir R et al. JAMA Intern Med 2014; 174(9): Pharmacomechanical adjuncts: Advantages Local administration of thrombolytic agent Reduced thrombolytic dose Reduced thrombolytic infusion time Decreasing bleeding complications Reduced ICU stay Reduced overall hospital treatment cost TORPEDO Trial Randomized trial N=183 Anticoagulation ± PEVI (Percutaneous endovascular intervention) Symptomatic, proximal DVT Femoropopliteal, iliac veins, or IVC Outcomes 6 months, final FU Recurrent VTE PTS 2 new symptoms + clinical sign (edema + reflux or venous stasis changes) Sharifi M et al. J Endovasc Ther 2012; 19: TORPEDO Trial 50% with no known history of DVT had venographic evidence of prior DVT TORPEDO Trial All patients had IVC filter placed before PEVI Infusion thrombolysis 37% Balloon venoplasty 76% Stenting 30% Total 47 stents: 21 in femoropopliteal veins Sharifi M et al. J Endovasc Ther 2012; 19: Sharifi M et al. J Endovasc Ther 2012; 19:
7 TORPEDO Trial Primary Endpoints at 30 Months PEVI N=88/91 Control N=81/92 P value PTS 6 (6.8%) 24 (29.6%) <.001 VTE 4 (4.5%) 13 (16.0%).02 PEVI is superior to anticoagulation alone in reducing PTS and VTE Limitations PTS not defined by validated scale PEVI more likely to be on aspirin and Plavix Aspirin with RR 0.37 (95% CI ) for PTS Sharifi M et al. J Endovasc Ther 2012; 19: Pharmacomechanical Catheter Directed Thrombolysis: Patient Selection! Highest anatomical extent of DVT Iliofemoral DVT Length and degree of symptoms Acute <14 days Risk factors for PTS Risk factors for bleeding Functional status Vedantham S. Tech Vasc Interv Radiol 2014; 17(2):103-8 Venous Stenting Recognition and treatment of obstructive lesions of iliac veins impacts success of CDT Criteria for stenting Pressure gradient of 5 mmhg? 50% stenosis by IVUS Venous collaterals Self expanding stents Elastic recoil after venoplasty from fibrosis Oversized (14-16 mm) Baekgaard N et al. Phlebology 2014; 29(15): Baekgaard N et al. Phlebology 2014; 29(15): Venous Stenting Pooled analysis 19 studies (N=1046) CDT ± percutaneous mechanical thrombectomy Acute DVT in 88%, Iliofemoral DVT 66% Stents in 46% National Venous Registry CDT in 303 limbs in 287 of 473 patients with DVT Acute DVT in 85%, Iliofemoral DVT 71% Stents 33% Patency 1 year: 74% with iliac stent vs 53% without (P<.001) Vedantham S. et al. J Vasc Interv Radiol 2009; 20:S Mewissen MW et al. Radiology 1999; 211(1): Durable Patency after Venous Stenting Retrospective analysis N=61: CDT + venous stenting Acute iliofemoral DVT ( 10 days) 92% 88% 90% 85% Xue G et al. Ann Vasc Surg 2014; 28:
8 Durable Patency after Venous Stenting Retrospective analysis N=32: CDT in 92% + iliac vein stenting Acute DVT 78% Compression Stockings: Significant Reduction in PTS Proximal DVT Active stockings vs no stockings for 2 years Outcome PTS (5 years FU) Study Timing Group N PTS P value Brandjes 2-3 weeks Stockings 96 20% <.001 Control 98 47% Prandoni 5-10 days Stockings %.011 Control % Warner CJ et al. Vasc and Endovasc surg 2013; 47(5): Brandjes DPM et al. Lancet 1997; 349: Prandoni P et al. Ann Intern Med 2004; 141(4): Compression Stockings: Sox Trial Multicenter, randomized trial 1 st proximal DVT <40% common femoral and iliac veins Active vs placebo elastic compression stockings (ECS) for 2 years mmhg vs <5 mmhg at ankle Applied within 2 weeks Outcome: PTS at 6 months Sox Trial: PTS by Ginsberg s criteria 1º outcome: Leg pain + swelling 1 month HR 1.13, 95% CI ( ) Kahn SR et al Lancet 2014; 383: Kahn SR et al Lancet 2014; 383: Sox Trial: PTS by Villalta Score 2º outcome: 5 or venous ulcer No difference in outcomes HR 1.00, 95% CI ( ) Findings do not support routine use of elastic compression stockings after DVT Kahn SR et al Lancet 2014; 383: Kahn SR et al Lancet 2014; 383:
9 Sox Trial: Limitations in Methodology Timing of ECS application (delayed) Fitting of ECS (mailed, no training) Evaluation of compliance (interview, frequent defined as 3-6 days) Compliance low Study 69% by 24 months Compliance Brandjes 56% used ECS 76% 3 always days/week at 24 Prandoni months 87% 80% of daytime hours Kahn (SOX) Not justifiable to entirely abandon compression stockings to prevent PTS 56% 3 days/week IDEAL DVT Study Multicenter, single blinded, assessor blinded randomized trial (Netherlands, Italy) Proximal DVT: N=864 All: ECS for 6 months Knee length graduated (ankle pressure 40 mmhg) Standard (24 months) vs Tailored Tailored: duration based on Villalta scores at 3 and 6 months Primary outcome: PTS at 24 months Ten Cate-Hoek A et al. BMJ Open 2014; 4:e Anticoagulation: Poor Quality and Increased PTS Calculated time spent < INR st DVT treated with vitamin K antagonist N=244 median FU 4.9 years 30% of time INR <2 33% developed PTS Patients with >50% subtherapeutic INR associated with increased risk of PTS OR 2.7, 95% CI 1.4 to 5.1 Van Dongen CJJ et al. J Thromb Haemost 2005; 3: Duration of Anticoagulation: >3 months for Unprovoked DVT 3 months + 24 months warfarin vs placebo PREVENT: low intensity warfarin (INR 1.5 to 2.0) vs placebo after full dose anticoagulation (6.5 months) Kearon C et al. NEJM 1999; 340:901-7 Ridker PM et al. NEJM 2003; 348: Warfarin N=79 Placebo N=83 P value Recurrent VTE 1.3% 27.4% <.0001 Bleeding 3.8% 0.09 Warfarin N=255 Placebo N=253 P value Recurrent VTE 2.6% 7.2% <.001 Bleeding %.25 Duration of Anticoagulation: >3 months for Unprovoked DVT Low vs conventional intensity warfarin Conventional N=369 Low Intensity N=369 HR Recurrent VTE 0.7% 1.9% 2.8 ( ) Bleeding 0.9% 1.1% 1.2 ( ) ACCP guidelines: Long term treatment Unprovoked proximal DVT/PE + low/moderating bleeding risk Cancer associated thrombosis Conclusions Iliofemoral DVT associated with significant PTS PCDT can reduce PTS Patient selection! Mechanism to identify patients with iliofemoral DVT Adjuncts to improve risks and outcomes of CDT Minimize thrombolysis time Treat residual stenosis Compression stockings for 6 months Indefinite anticoagulation if unprovoked Kearon C et al. NEJM 2003; 349:
Should We Be More Aggressive in the Treatment of Acute DVT?
DISCLOSURES Consultant Penumbra, Inc. UCSF Vascular Surgery Symposium April 6, 2017 K. Pallav Kolli, MD Assistant Professor of Clinical Radiology University of California, San Francisco 17 yo male, DVT
More informationThe Evidence Base for Treating Acute DVT
The Evidence Base for Treating Acute DVT Mr Chung Sim Lim Consultant Vascular Surgeon and Honorary Lecturer Royal Free London NHS Foundation Trust and University College London NIHR UCLH Biomedical Research
More informationAcute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT Trial)
Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT Trial) N Engl J Med. Volume 377(23):2240-2252. December 7, 2017 Wednesday, July 11, 2018, 1:00pm ET Guest
More informationNot all Leg DVT s are the Same: Which Patients Benefit from Interventional Therapy? Case 1:
12/16/2015 Not all Leg DVT s are the Same: Which Patients Benefit from Interventional Therapy? Constantino S.Peña, FSIR, FSCCT, FAHA Interventional Radiologist Medical Director, Vascular Imaging Miami
More informationTHERE IS NO ROLE FOR SURGICAL THERAPY FOR DVT
THERE IS NO ROLE FOR SURGICAL THERAPY FOR DVT Tara D. Balint, MD FACS Sentara RMH Thursday, June 14, 2018 1 Objectives of treatment for DVT Prevent death from PE Prevent recurrent VTE Prevent post-thrombotic
More informationVenous interventions in DVT
Venous interventions in DVT Sriram Narayanan Chief of Vascular and Endovascular Surgery, Tan Tock Seng Hospital A/Prof of Surgery, National University of Singapore ANTI-COAGULATION LMWH Warfarin x 6m Acute
More informationCopy Here. The Easy One.. What is the Role of Thrombus Removal in Acute Proximal DVT after ATTRACT? Deep Venous Thrombosis Spectrum
What is the Role of Thrombus Removal in Acute Proximal DVT after ATTRACT? Mitchell J. Silver DO FACC FSVM RPVI Director, Center for Critical Limb Care Riverside Methodist Hospital Ohio Health Heart and
More informationImplications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach
Implications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach Prof. I. Baumgartner Head Clinical and Interventional Angiology About the ACCP guidelines Widely
More informationThe evidence for venous interventions is evolving- many patients do actually benefit. Nils Kucher University Hospital Bern Switzerland
The evidence for venous interventions is evolving- many patients do actually benefit Nils Kucher University Hospital Bern Switzerland Disclosure Speaker name: Nils Kucher X X I have the following potential
More informationPrevention of VTE Sequelae: Post-thrombotic Syndrome and Chronic Thromboembolic Pulmonary Hypertension
Prevention of VTE Sequelae: Post-thrombotic Syndrome and Chronic Thromboembolic Pulmonary Hypertension Susan R. Kahn MD MSc Professor of Medicine, McGill University Director, Jewish General Hospital Centre
More information- Our patients with iliofemoral DVT - Effective thrombus removal with purely mechanical thrombectomy can lead to better outcomes
- Our patients with iliofemoral DVT - Effective thrombus removal with purely mechanical thrombectomy can lead to better outcomes Michael K. W. Lichtenberg, FESC Conflict of Interest - Disclosure Within
More information4/30/2018 CLOT+ In patients with an acute proximal deep vein thrombosis, pharmacomechanical catheter-directed thrombolysis does not reduce t
In patients with an acute proximal deep vein thrombosis, pharmacomechanical catheter-directed thrombolysis does not reduce the rate of post-thrombotic syndrome Question In patients who have symptomatic
More informationAggressive endovascular management of ilio-femoral DVT. thrombotic syndrome. is the key in preventing post
CACVS 2017 Aggressive endovascular management of ilio-femoral DVT is the key in preventing post thrombotic syndrome ALI AMIN MD, FACS,FACC, RVT CHIEF OF ENDOVASCULAR INTERVENTIONS READING HEALTH SYSTEM
More informationIleo Femoral DVT Review and Update
Ileo Femoral DVT Review and Update Ammar Safar, MD, FSCAI, FACC, FACP, RPVI Interventional Cardiology & Endovascular Medicine Deep Vein Thrombosis Venous thromboembolism is a major national health problem,
More informationJ Jpn Coll Angiol, 2009, 49:
Online publication August 27, 2009 1 2 J Jpn Coll Angiol, 2009, 49: 247 254 deep vein thrombosis, thrombolytic therapy, catheter-directed thrombolysis, inferior vena cava filter, pulmonary thromboembolism
More informationSurgical approach for DVT. Division of Vascular Surgery Department of Surgery Seoul National University College of Medicine
Surgical approach for DVT Seung-Kee Min Division of Vascular Surgery Department of Surgery Seoul National University College of Medicine Treatment Options for Venous Thrombosis Unfractionated heparin &
More informationCanadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON
Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON How to Prevent and Manage the Post-Thrombotic Syndrome? Jean-Philippe Galanaud Clinical Thromboembolism & Division of GIM Sunnybrook,
More informationIntervention for Deep Venous Thrombosis and Pulmonary Embolus
Intervention for Deep Venous Thrombosis and Pulmonary Embolus Michael R. Jaff, DO Paul and Phyllis Fireman Endowed Chair in Vascular Medicine Massachusetts General Hospital Professor of Medicine Harvard
More informationTechniques for thrombus removal in acute DVT Benefits of an Endovascular Approach for Rapid Flow Restoration in DVT
Techniques for thrombus removal in acute DVT Benefits of an Endovascular Approach for Rapid Flow Restoration in DVT Michael K. W. Lichtenberg, MD, FESC Vascular Centre Arnsberg, Germany Disclosure Speaker
More informationOptimal Utilization of Thrombolytics
April 8-9, 2011 New York LaGuardia Marriott COMPLETE MANAGEMENT OF VENOUS DISEASE Optimal Utilization of Thrombolytics Anthony J. Comerota, MD, FACS, FACC Director, Jobst Vascular Institute Adjunct Professor
More informationAnticoagulation therapy following endovascular treatment of iliofemoral deep vein thrombosis
Anticoagulation therapy following endovascular treatment of iliofemoral deep vein thrombosis Tim Sebastian, M.D. University Hospital Zurich Clinic for Angiology Disclosure Speaker name: Tim Sebastian I
More informationInterventional Treatment VTE: Radiologic Approach
Interventional Treatment VTE: Radiologic Approach Hae Giu Lee, MD Professor, Dept of Radiology Seoul St. Mary s Hospital The Catholic University of Korea Introduction Incidence High incidence: 250,000-1,000,000/year
More informationPharmaco-mechanical techniques stand alone procedures? Peter Neglén, MD, PhD SP Vascular Center Limassol Cyprus
Pharmaco-mechanical techniques stand alone procedures? Peter Neglén, MD, PhD SP Vascular Center Limassol Cyprus Faculty Disclosure Peter Neglén, M.D., Ph.D Stockholder/Founder of Veniti, Inc. Member, Medical
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of Interventional procedure overview of ultrasound-enhanced, catheterdirected thrombolysis
More informationTreatment of Chronic DVT with EKOS: Reproducing ACCESS PTS Data in Every Day Clinical Practice
Treatment of Chronic DVT with EKOS: Reproducing ACCESS PTS Data in Every Day Clinical Practice Mert Dumantepe, MD Acibadem Altunizade Hospital, Istanbul, Turkey Department of Cardiovascular Surgery Disclosure
More informationPost-Thrombotic Syndrome Prevention and Management. Dr. Ashwini Bennett
Post-Thrombotic Syndrome Prevention and Management Dr. Ashwini Bennett Disclosures No disclosures relevant to this presentation Outline Importance of VTE and PTS Aetiology of PTS PTS risk factors PTS clinical
More informationAcute Versus Chronic DVT Imaging in the Vascular Lab Heather Gornik, MD, RVT, RPVI
Acute Versus Chronic DVT Imaging in the Vascular Lab Heather Gornik, MD, RVT, RPVI Cleveland Clinic Heart and Vascular Institute Heather L. Gornik, MD has the following relationships to disclose: CVR Global
More informationImproved clinical outcomes Evidence on venous mechanical thrombectomy followed by stenting
Improved clinical outcomes Evidence on venous mechanical thrombectomy followed by stenting Michael K. W. Lichtenberg, MD, FESC Vascular Centre Arnsberg, Germany German Venous Centre Arnsberg, Germany Disclosure
More informationMichael Meuse, M.D. Vascular and Interventional Radiology
Michael Meuse, M.D. Vascular and Interventional Radiology Iliac Vein Compression Syndrome Left CIV compressed by right CIA Virchow 1851: DVT L>R May and Thurner 1954: venous spurs Cockett and Thomas 1965:
More informationPercutaneously Inserted AngioVac Suction Thrombectomy for the Treatment of Filter-Related. Iliocaval Thrombosis
Percutaneously Inserted AngioVac Suction Thrombectomy for the Treatment of Filter-Related Iliocaval Thrombosis Faiz D. Francis, DO; Gianvito Salerno, MD; Sabbah D. Butty, MD Abstract In the setting of
More informationIncidence and interventions for post-thrombotic syndrome
Review Article Incidence and interventions for post-thrombotic syndrome Jeffrey J. Farrell, Christopher Sutter, Sidhartha Tavri, Indravadan Patel Department of Radiology, University Hospitals Cleveland
More informationDr Paul Thibault. Phlebologist & Assistant Editor Phlebology (International Journal) Australasian College of Phlebology
Dr Paul Thibault Phlebologist & Assistant Editor Phlebology (International Journal) Australasian College of Phlebology Prescribing Effective Compression and PTS Dr Paul Thibault Phlebologist, Newcastle,
More informationImproved clinical outcomes Evidence on venous thrombectomy followed by stenting
Improved clinical outcomes Evidence on venous thrombectomy followed by stenting Michael K. W. Lichtenberg, MD, FESC Vascular Centre Arnsberg, Germany Venous Centre Arnsberg, Germany Disclosure Speaker
More informationChronic Iliocaval Venous Occlusive Disease
none Chronic Iliocaval Venous Occlusive Disease David Rigberg, M.D. Clinical Professor of Surgery Division of Vascular Surgery University of California Los Angeles Chronic Venous Occlusive Disease Chronic
More informationMechanical treatment for acute DVT. Laurent Casbas, MD Toulouse, France
Laurent Casbas, MD Toulouse, France Disclosure of Interest Speaker name: Laurent Casbas I have the following potential conflicts of interest to report: Consulting Medtronic General Electric Acute Venous
More informationMeissner MH, Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, et al. J Vasc Surg. 2012;55:
Early thrombus removal strategies for acute deep venous thrombosis: Clinical Practice Guidelines of the Society for Vascular Surgery and the American Venous Forum Meissner MH, Gloviczki P, Comerota AJ,
More informationPost-thrombotic syndrome (PTS), often the
Revascularization of Chronic Venous Occlusion in the Setting of Post-Thrombotic Syndrome Jon George, MD; Deepakraj Gajanana; Sean Janzer; Vincent Figueredo; Dennis Morris From the Einstein Heart and Vascular
More informationStatus of anticoagulation therapy in 2016: Is there a need for venous revascularization?
Status of anticoagulation therapy in 2016: Is there a need for venous revascularization? Rupert M. Bauersachs Dept. of Vascular Medicine, Darmstadt Center of Thrombosis Hemostasis, Mainz Status of anticoagulation
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of Interventional procedure overview of ultrasound-enhanced, catheterdirected thrombolysis
More information4/23/2009. September 15, 2008
The Current Treatment of Deep Venous Thrombosis: Are We Doing Enough? George H. Meier, MD Professor and Chief Division of Vascular Surgery University of Cincinnati College of Medicine Cincinnati, Ohio
More informationCatheter-directed thrombolysis of deep vein thrombosis: literature review and practice considerations
Review Article Catheter-directed thrombolysis of deep vein thrombosis: literature review and practice considerations Drew Fleck 1, Hassan Albadawi 1, Fadi Shamoun 2, Grace Knuttinen 1, Sailendra Naidu
More informationPEARL Registry Update Overview Venous Arterial AV Access
PEARL Registry Update Overview Venous Arterial AV Access PEARL Registry Overview (as of 10 Sep12*) Overview Venous Arterial AV Access HOME Topic Data Support Comments Study Design Prospective, non-randomized,
More informationComplex Iliocaval Reconstruction PNEC. Seattle WA. Bill Marston MD Professor, Div of Vascular Surgery University of N.
Complex Iliocaval Reconstruction 2017 PNEC. Seattle WA Bill Marston MD Professor, Div of Vascular Surgery University of N. Carolina DISCLOSURES William Marston, MD Consultant/Advisory Board: Veniti, Cardinal
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationEarly clinical outcomes of a novel rheolytic directional thrombectomy technique for patients with iliofemoral deep vein thrombosis
56 Original communication Early clinical outcomes of a novel rheolytic directional thrombectomy technique for patients with iliofemoral deep vein thrombosis Jörn F. Dopheide 1, Tim Sebastian 1, Rolf P.
More informationThe Conservative and Active Management of Post Thrombotic Syndrome
The Conservative and Active Management of Post Thrombotic Syndrome Stephen Black Consultant Vascular Surgeon Clinical Lead for Venous and Lymphoedema Surgery Guys and St Thomas Hospital London How important
More informationVenous thromboembolic diseases: diagnosis, management and thrombophilia testing (2012) NICE guideline CG144
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2012) NICE guideline CG144 Appendix A: Summary of new evidence from Summary of evidence from previous year Diagnosis Diagnostic
More informationPercutaneous Mechanical Thrombectomy for Acute Iliofemoral DVT with the Aspirex Catheter: The Dijon Experience
JFICV 2018, Beaune Percutaneous Mechanical Thrombectomy for Acute Iliofemoral DVT with the Aspirex Catheter: The Dijon Experience Prof. Romaric LOFFROY, MD, PhD, FCIRSE Chief, Department of Vascular and
More informationBY DAVID GILLESPIE, MD; MARCIA JOHANSSON, RN, MS; AND CAROLYN GLASS, MD
Stent Placement fter DVT Thrombolysis/ Mechanical Thrombectomy Which patients should be stented and which should not? Y DVID GILLESPIE, MD; MRCI JOHNSSON, RN, MS; ND CROLYN GLSS, MD It is an exciting time
More informationAspirex for Upper and Lower Extremity DVT
Aspirex for Upper and Lower Extremity DVT Steven Kum MD Vascular & Endovascular Surgeon Director of Vascular Service Changi General Hospital Singapore Disclosure Speaker name:... I have the following potential
More informationPEARL REGISTRY Post Market Registry
PEARL REGISTRY Post Market Registry Real World Use of the AngioJet Thrombectomy System in the Peripheral Vascular System PI-315422-AA JUN2015 Objectives AngioJet Action Enrollment General Indications &
More informationManagement of Post-Thrombotic Syndrome
Management of Post-Thrombotic Syndrome Thanainit Chotanaphuti Phramongkutklao College of Medicine Bangkok, Thailand President of CAOS Asia President of Thai Hip & Knee Society President of ASEAN Arthroplasty
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC 1 st workshop: update to VTE guidelines in 2016 2 nd workshop: VTE controversies + new horizons André Roussin MD, FRCP, CSPQ CHUM
More informationNo financial disclosures
7/23/2013 Which patients with acute lower extremity DVT should definitely, probably, and possibly be treated with catheter directed thrombolysis? Akhilesh K. Sista, M.D. Assistant Professor, Division of
More informationBC Vascular Day. Contents. November 3, Abdominal Aortic Aneurysm 2 3. Peripheral Arterial Disease 4 6. Deep Venous Thrombosis 7 8
BC Vascular Day Contents Abdominal Aortic Aneurysm 2 3 November 3, 2018 Peripheral Arterial Disease 4 6 Deep Venous Thrombosis 7 8 Abdominal Aortic Aneurysm Conservative Management Risk factor modification
More informationVenous stenting in Marseille
Venous stenting in Marseille Olivier HARTUNG, MD, MSc CHU Nord, Marseille, FRANCE Disclosure Speaker name: Olivier HARTUNG I have the following potential conflicts of interest to report: x Consulting :
More informationA Dedicated Venous Self-expanding Oblique Hybrid Nitinol Stent (Sinus-Obliquus Stent)
A Dedicated Venous Self-expanding Oblique Hybrid Nitinol Stent (Sinus-Obliquus Stent) Anna Stuck, Rolf P. Engelberger, Nils Kucher Division of Angiology Cantonal Hospital Fribourg & Bern University Hospital
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationVERNACULAR Trial & Clinical Experience with the VENOVO Venous Stent
Stephen Black, MD VERNACULAR Trial & Clinical Experience with the VENOVO Venous Stent 1 Speaker Disclaimers The speakers presentation today is on behalf of Bard Peripheral Vascular, Inc. Any discussion
More information5 year quality of life data after EKOS treatment in acute DVT
5 year quality of life data after EKOS treatment in acute DVT Jochen Grommes MD European Vascular Center Aachen-Maastricht GxUS-EKO-2016-0006 LINC 2016 Disclosure of speaker s interests conflict of interest
More informationCatheter direct thrombolysis: Role of actilyse in treatment of acute deep venous thrombosis
The Egyptian Journal of Radiology and Nuclear Medicine (2013) 44, 57 62 Egyptian Society of Radiology and Nuclear Medicine The Egyptian Journal of Radiology and Nuclear Medicine www.elsevier.com/locate/ejrnm
More informationWith All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis
BRIGHAM AND WOMEN S HOSPITAL With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis Gregory Piazza, MD, MS Division of Cardiovascular Medicine Brigham and Women s Hospital April
More informationStarting with deep venous treatment
Starting with deep venous treatment Carsten Arnoldussen, MD Interventional Radiologist Maastricht University Medical Centre, Maastricht VieCuri Medical Centre, Venlo The Netherlands Background Maastricht
More informationSuccessful recanalisation of venous thrombotic occlusions with Aspirex mechanical thrombectomy. Michael K. W. Lichtenberg
Successful recanalisation of venous thrombotic occlusions with Aspirex mechanical thrombectomy Michael K. W. Lichtenberg Disclosure Speaker name: Michael Lichtenberg... I have the following potential conflicts
More informationUltrasound-assisted catheter-directed thrombolysis: Does it really work? The BERNUTIFUL trial
Ultrasound-assisted catheter-directed thrombolysis: Does it really work? The BERNUTIFUL trial Rolf P. Engelberger Division of Angiology CHUV, Lausanne & Inselspital, Bern Switzerland Disclosure Speaker
More informationDeterminants of Early and Long-term Efficacy of Catheter-directed Thrombolysis in Proximal Deep Vein Thrombosis
CLINICAL STUDY Determinants of Early and Long-term Efficacy of Catheter-directed Thrombolysis in Proximal Deep Vein Thrombosis Ylva Haig, MD, Tone Enden, MD, PhD, Carl-Erik Slagsvold, MD, PhD, Leiv Sandvik,
More informationImage-Guided Approach to Treatment of Patients with Nonthrombotic
Image-Guided Approach to Treatment of Patients with Nonthrombotic May Thurner Syndrome Brian DeRubertis, MD, FACS Associate Professor of Surgery Division of Vascular Surgery UCLA School of Medicine Los
More informationHow to best approach chronic venous occlusions?
How to best approach chronic venous occlusions? Prof. Nils Kucher Director Venous Thromboembolism Reseach Group University Hospital Bern nilskucher.com Disclosure Speaker name: Nils Kucher X X I have the
More informationVenous stent experience in Arnsberg Michael K. W. Lichtenberg MD, FESC
Venous stent experience in Arnsberg Michael K. W. Lichtenberg MD, FESC IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label
More informationDEEP VENOUS THROMBOSIS A PRACTICAL APPROACH TO IMPROVING CLINICAL OUTCOMES
DEEP VENOUS THROMBOSIS A PRACTICAL APPROACH TO IMPROVING CLINICAL OUTCOMES Jose M. Borromeo M.D. Vascular Surgeon Iowa Heart Center Disclosures: AstraZeneca Pharmaceuticals Cook CVRx LeMaitre Vascular,
More informationTechnique de recanalisation: mon expérience avec Aspirex
JFICV 2017, Deauville Thrombose veineuse profonde aiguë en 2017 Technique de recanalisation: mon expérience avec Aspirex Romaric LOFFROY Département de Radiologie Diagnostique et Thérapeutique CHU Hôpital
More informationEmerging Tools for Lytic-Free, Single-Session Treatment of Venous Thromboembolic Disease
FEATURED TECHNOLOGY THE CLOTTRIEVER AND FLOWTRIEVER SYSTEMS Emerging Tools for Lytic-Free, Single-Session Treatment of Venous Thromboembolic Disease The ClotTriever Outcomes (CLOUT) registry principal
More informationVenous Thrombosis. Magnitude of the Problem. DVT 2 Million PE 600,000. Death 60,000. Estimated Cost of VTE Care $1.5 Billion/year.
Venous Thrombosis Magnitude of the Problem DVT 2 Million Postthrombotic Syndrome 800,000 PE 600,000 Death 60,000 Silent PE 1 Million Pulmonary Hypertension 30,000 Estimated Cost of VTE Care $1.5 Billion/year
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationDeep Venous Thrombosis: The Opportunity at Hand
Vascular and Interventional Radiology Review Vedantham DVT: The Opportunity at Hand Vascular and Interventional Radiology Review Suresh Vedantham 1 Vedantham S FOCUS ON: Keywords: ATTRACT Trial, deep venous
More informationPatient population. Study objectives. Randomization and stratification. Study design, organization, and regulatory status. Standard DVT therapy
Rationale and design of the ATTRACT Study: A multicenter randomized trial to evaluate pharmacomechanical catheter-directed thrombolysis for the prevention of postthrombotic syndrome in patients with proximal
More informationPrevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales
Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales Merimbula, 6 th November 2010 University of Sydney Department of Surgery Westmead Hospital
More informationControversies in Venous Thromboembolism
Controversies in Venous Thromboembolism Menaka Pai, BSc MSc MD FRCPC Assistant Professor, Department of Medicine, McMaster University Associate Member, Department of Pathology and Molecular Medicine, McMaster
More informationVIVO-EU Results: Prospective European Study of the Zilver Vena TM Venous Stent in the Treatment of Symptomatic Iliofemoral Venous Outflow Obstruction
VIVO-EU Results: Prospective European Study of the Zilver Vena TM Venous Stent in the Treatment of Symptomatic Iliofemoral Venous Outflow Obstruction Gerard J O Sullivan, M.D. and Jennifer McCann-Brown,
More informationMethods of Thrombus Fragmentation & Extraction. Methods of Thrombus Extraction
Thrombus Fragmentation and Extraction: Clinical Evidence and Practical Application No Relevant Disclosures Venita Chandra, MD Clinical Assistant Professor of Surgery Division of Stanford Medical School,
More informationDeep Venous Pathology. Eberhard Rabe Department of Dermatology University of Bonn Germany
Deep Venous Pathology Eberhard Rabe Department of Dermatology University of Bonn Germany Disclosures None for this presentation Consultant: Sigvaris, EUROCOM Speakers bureau: Bayer Vital, Aspen, Boehringer,
More informationRe-intervention for occluded iliac vein stents
Review Article Re-intervention for occluded iliac vein stents Stacey Black 1, Amy Janicek 2, M. Grace Knuttinen 3 1 University of Arizona, Tucson, Arizona, USA; 2 Arizona State Radiology, Tucson, Arizona,
More informationThe purpose of this scientific statement is to provide an
AHA Scientific Statement The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies A Scientific Statement From the American Heart Association Susan R. Kahn, MD, MSc, FRCPC,
More informationWhat is the optimal time window for treating deep venous thrombosis? Acute vs subacute vs chronic
What is the optimal time window for treating deep venous thrombosis? Acute vs subacute vs chronic Peter A. Schneider, MD Chief of Vascular Therapy Kaiser Foundation Hospital Honolulu, Hawaii Disclosure
More informationCatheter-directed thrombolysis for iliofemoral deep vein thrombosis
Original article Catheter-directed thrombolysis for iliofemoral deep vein thrombosis J. H. Saunders, P. H. Arya, S. Abisi, Y. P. Yong, S. MacSweeney, B. Braithwaite and N. Altaf Department of Vascular
More informationClinical results of venous stents. Michael K. W. Lichtenberg MD, FESC
Clinical results of venous stents Michael K. W. Lichtenberg MD, FESC Conflict of Interest - Disclosure Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation
More informationCurrent issues in the management of Superficial Vein Thrombosis - SVT
Current issues in the management of Superficial Vein Thrombosis - SVT Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, School of Health Sciences,
More informationREKANALISATION CHRONISCH VENÖSER VERSCHLÜSSE. Michael K. W. Lichtenberg, FESC
REKANALISATION CHRONISCH VENÖSER VERSCHLÜSSE Michael K. W. Lichtenberg, FESC Conflict of Interest - Disclosure Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement
More informationFuture Devices of Venous Interventions
Future Devices of Venous Interventions Director of Peripheral Vascular Medicine Department of Shin Kong Wu Ho-Su Memorial Hospital, Taiwan Interventional Cardiologist Tien-Yu Wu MD Disclosure Speaker name:...
More informationDiscussion Leader: Doug Bias, M.D.
In low-risk patients with isolated calf DVT (IDDVT), what is the morbidity risk of treating with repeat ultrasound/observation versus anticoagulation? Discussion Leader: Doug Bias, M.D. Clinical Scenario:
More informationENHANCING YOUR OPTIONS
ANGIOJET ULTRA Thrombectomy System ENHANCING YOUR OPTIONS FOR RESTORING FLOW When you need the versatility and power to restore flow Refined from experience in over 700,000 cases worldwide, today s AngioJet
More informationWhat Really Matters to Patient is QOL: Veniti Virtus Venous Feasibility Trial
DISCLOSURES Speaker name: Lowell S. Kabnick, MD, FACS... I have the following potential conflicts of interest: Consultant and shareholder, VENITI, Inc. Consultant to BARD What Really Matters to Patient
More informationTop 5 (or so) Hematology Consults. Tom DeLoughery, MD FACP FAWM. Oregon Health and Sciences University DISCLOSURE
Top 5 (or so) Hematology Consults Tom FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none 1 What I am Talking About
More informationACR Appropriateness Criteria Suspected Lower Extremity Deep Vein Thrombosis EVIDENCE TABLE
. Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg 003; 5():-5.. Hamper UM, DeJong MR, Scoutt LM. Ultrasound
More informationPopliteal Aneurysm: When is surgical therapy indicated? PROF. GRZEGORZ OSZKINIS
Popliteal Aneurysm: When is surgical therapy indicated? PROF. GRZEGORZ OSZKINIS Asymptomatic mass - 38-40%will develop symptoms at a rate of 14%/yr Intermittent claudic ation (chronic ischemia) - 25%-40%
More informationEvidence for endovascular therapy of iliofemoral DVT: CAVENT, ATTRACT, CAVA and more to come
Evidence for endovascular therapy of iliofemoral DVT: CAVENT, ATTRACT, CAVA and more to come Stephen Black Consultant Vascular Surgeon Reader in Venous Surgery Or rephrased To lyse or not to lyse: that
More informationCURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
More informationDVT - initial management NSCCG
Background information Information resources for patients and carers Updates to this care map Synonyms Below knee DVT and bleeding risks Patient with confirmed DVT Scan confirms superficial thrombophlebitis
More informationNOTE: Deep Vein Thrombosis (DVT) Risk Factors
Deep Vein Thrombosis (DVT) Deep Vein Thrombosis (DVT) is the formation of a blood clot, known as a thrombus, in the deep leg vein. It is a very serious condition that can cause permanent damage to the
More informationDisclosures. What is a Specialty Vein Clinic? Prevalence of Venous Disease. Management of Venous Disease: an evidence based approach.
Management of Venous Disease: an evidence based approach Disclosures Ed Boyle, MD Andrew Jones, MD Dr. Ed Boyle and Dr. Andrew Jones disclose Grants/research support: Medtronic, BTG International, Clearflow,
More information